Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS). Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior…
Merck & Co. Inc. reported positive survival data from its pivotal Phase 3 TroFuse-015 trial for an investigational therapy targeting advanced gastric cancer. Sacituzumab tirumotecan, the experimental drug, demonstrated a statistically significant improvement in overall survival compared to standard treatment options in patients with locally advanced unresectable or metastatic gastric adenocarcinoma who had received at least two prior systemic therapies.
The study marks the first time a TROP2-directed antibody-drug conjugate (ADC) has improved overall survival in a global Phase 3 study for this specific cancer type. Trial data revealed no new safety concerns, and Merck is currently evaluating sacituzumab tirumotecan as both a monotherapy and in combination with immunotherapies across a range of cancer types.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.